Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Slides:

Advertisements

Similar presentations

1 Hypertension 2002: An Overview. 2 Leading Risks For Death (World Health Organization 1995)

Advertisements

LONG TERM BLOOD PRESSURE MONITORING J. Dušek 1, B. Fišer 1, J. Siegelová 1, P. Vank 1, G. Cornelissen 2, F. Halberg 2 1 Masaryk University, Brno 2 Halberg.

The Indian Polycap Study (TIPS). Lancet 2009 Mar 30 [Epub]

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.

Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.

CSM-1 Patients With and Without Obesity LSM Difference and 95% CI in BP (230, 231 Pooled) † Diastolic BP Overall (N = 1,191) Obese.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.

Journal Club February 7, 2014 Sadie T. Velásquez, MD.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Exercise and Weight Loss Reduce Blood Pressure in.

Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Externally Delivered Focused Ultrasound for Renal.

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Community Teaching Project: Hypertension Presented by: Mariel Alvarez, Michelle Vickers, Andy Nguyen, Lalita Poon, Minh Luong.

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,

Volume 54, Pages S135-S139 (December 1998)

Figure 1. Schedule of the study

From ESH 2016 | POS 3C: Chiara Lorenzi, MD

Copyright © 2010 American Medical Association. All rights reserved.

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis William L. Baker, PharmD, FCCP, Lindsay.

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Copyright © 2011 American Medical Association. All rights reserved.

Flowchart of participants

Neal B, et al. Diabetes Care 2015;38:403–411

Aliskiren and Valsartan for Antihypertensive Therapy Trial

HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Copyright © 2007 American Medical Association. All rights reserved.

Circ Cardiovasc Qual Outcomes

by Katie Ayers, Loretta M. Byrne, Anthony DeMatteo, and Nancy J. Brown

Oana Dickinson et al. JACEP 2016;2:

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Continuous glucose monitoring tracings of two patients with type 1 diabetes (one patient per panel) on a day when aerobic exercise was performed (open.

Volume 93, Issue 1, Pages (January 2018)

Figure 1 Changes in relative plasma volume (RPV)

Chapter 28 Nutrition, Lifestyle, and Hypertension

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Ambulatory BP Monitoring vs Office BP

Cumulative incidence of diabetes for participants in the Diabetes Prevention Program. Cumulative incidence of diabetes for participants in the Diabetes.

William T. Abraham et al. JCHF 2015;3:

Ambulatory BP Monitoring vs Office BP

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

SYMPLICITY: not all that simple

Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

Volume 54, Pages S135-S139 (December 1998)

Volume 64, Issue 2, Pages (August 2003)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Pseudopheochromocytoma Secondary to Brimonidine Ophthalmic Solution

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Atrasentan reduces albuminuria in diabetic apoE KO mice.

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

End point Valsartan Valsartan+HCTZ p

Volume 73, Issue 11, Pages (June 2008)

Philippe Pibarot et al. JIMG 2015;8:

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Low-volume HIIT leads to rapid improvements in glucose control in individuals with type 2 diabetes. Low-volume HIIT leads to rapid improvements in glucose.

Aliskiren, the orally effective renin inhibitor, provides antihypertensive efficacy at least equivalent to the ARB irbesartan in patients with hypertension.

The combined effects of low sodium and the DASH diet according to baseline blood pressure. The combined effects of low sodium and the DASH diet according.

Presentation transcript:

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive patients after 6 weeks of treatment. Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive patients after 6 weeks of treatment. Values shown are ± SE. SBP inferences are based on an ad hoc analysis. *P ≤ 0.001 for dose-related trend tests for change from baseline in mean diastolic and systolic blood pressure for all carvedilol CR doses with placebo. DBP, diastolic blood pressure; SBP, systolic blood pressure. Reprinted with permission from Ref. 66. Janet B. McGill Clin Diabetes 2009;27:36-46 ©2009 by American Diabetes Association